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ORIGINAL ARTICLE
Background: Lymphovascular space invasion (LVI) is an established 
negative prognostic factor and an indication for postoperative radia-
tion therapy in many malignancies. The purpose of this study was to 
evaluate LVI in patients with early-stage non–small-cell lung cancer, 
undergoing surgical resection.
Methods: All patients who underwent initial surgery for pT1-3N0-2 
non–small-cell lung cancer at Duke University Medical Center from 
1995 to 2008 were identified. A multivariate ordinal regression was 
used to assess the relationship between LVI and pathologic hilar and/
or mediastinal lymph node (LN) involvement. A multivariate Cox 
regression analysis was used to evaluate the relationship of LVI and 
other clinical and pathologic factors on local failure (LF), freedom 
from distant metastasis (FFDM), and overall survival (OS). Kaplan-
Meier methods were used to generate estimates of LF, FFDM, and 
OS in patients with and without LVI.
Results: One thousand five hundred and fifty-nine patients were iden-
tified. LVI was independently associated with the presence of regional 
LN involvement (p < 0.001) along with lobar (versus sublobar) resec-
tions (p < 0.001), and an open thoracotomy (versus video-assisted 
thoracoscopic surgery). LVI was not independently associated with 
LF on multivariate analysis (hazard ratio [HR] = 1.23, p = 0.25), but 
was associated with a lower FFDM (HR 1.52, p = 0.005) and OS 
(HR 1.26, p = 0.015). In addition, multivariate analysis showed that 
LVI was strongly associated with increased risk of developing distant 
metastases (HR = 1.75, p = 0.006) and death (HR = 1.53, p = 0.003) 
in adenocarcinomas but not in squamous carcinomas.
Conclusions: LVI is associated with an increased risk of harboring 
regional LN involvement. LVI is also an adverse prognostic factor for 
the development of distant metastases and long-term survival.
Key Words: Lymphovascular invasion, Lung cancer, Local failure.
(J Thorac Oncol. 2012;7: 1141–1147)
Stage is currently the dominant factor affecting adjuvant-treatment recommendations in resected non–small-cell 
lung cancer (NSCLC).1 Practice guidelines have been pro-
foundly influenced by three recent randomized trials dem-
onstrating a survival benefit with the addition of adjuvant 
chemotherapy.2–4 This benefit has been largely confined to N1 
to N2 disease,5 although subset analyses have suggested that 
chemotherapy is also advantageous for patients with larger 
stage I tumors.4,6 The role of postoperative radiation therapy is 
less well defined, but is generally recommended for patients 
with involved mediastinal lymph nodes (LNs) (N2) or positive 
surgical margins.
Elucidation of high-risk pathologic features in resected 
NSCLC may help to further stratify patients into risk groups, 
allowing for further refinement of adjuvant treatment recom-
mendations. For example, lymphovascular space invasion 
(LVI) is an adverse prognostic factor for numerous solid 
tumors. Furthermore, the presence of LVI is an independent 
indication for postoperative radiation therapy in several epi-
thelial malignancies, including cervix,7 endometrial,8 vulvar,9 
and head and neck cancers.10
Several studies have demonstrated that LVI is also a 
poor prognostic factor for recurrence-free and overall survival 
(OS) in NSCLC.11–15 One recent study has demonstrated that 
presence of LVI in a biopsy specimen is an independent risk 
factor for death and metastatic progression for patients treated 
with definitive chemoradiotherapy.16 However, the influence of 
LVI on adjuvant-treatment recommendations after resection is 
unclear. Current NCCN guidelines are somewhat ambiguous, 
stating that the presence of LVI is considered “high-risk”.17 
Whether LVI increases the risk of local or distant recurrence 
(or both) is unknown. In addition to this question, we also 
sought to investigate the association between the presence of 
LVI in the primary tumor and the risk of harboring disease in 
hilar and/or mediastinal LNs.
METHODS
This Institutional Review Board-approved study identi-
fied all patients who underwent surgery for T1-3N0-2 NSCLC 
at Duke University between 1995 and 2008. Patients were 
excluded if they received preoperative chemotherapy and/or 
preoperative radiation therapy, or had a prior history of lung 
cancer. Medical records and pertinent radiological imaging 
were reviewed to characterize each patient’s demographic 
information, obtain surgical and pathological details, and 
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score patterns of failure after surgery. The pathologic stag-
ing of patients in this cohort reflects the updated tumor, node, 
metastasis staging for NSCLC.1
Between  1995 and 1997, lung tumor specimens were 
interpreted by multiple pathologists at Duke University 
Medical Center. After 1998, all specimens were interpreted 
by a single pathologist with a special interest in pulmonary 
pathology (TAS). Hematoxylin and eosin stains were per-
formed on all specimens. LVI was reported when tumor cells 
were demonstrated on histologic examination within lym-
phatic channels, veins/venules, and/or arteries/arterioles.
Patterns of failure were assessed by means of follow-up 
imaging studies and information obtained from procedures such 
as computed-tomography (CT)–guided transthoracic biopsies, 
bronchoscopy, endobronchial ultrasound, and mediastinoscopy, 
etc. A local failure (LF) was scored when disease recurred at 
the surgical resection margin or regional LNs (ipsilateral hilum 
and/or mediastinum). Nodal failures in the ipsilateral hilum or 
mediastinum were defined as a new or enlarging LN of 1 cm or 
more on short axis on CT, and/or hypermetabolic on positron 
emission tomography imaging, which in the patient’s subse-
quent clinical follow-up was consistent with disease progres-
sion. All cases of possible local and distant recurrence were 
reviewed by two authors (CK and JB/KH) to ensure accuracy. 
All patients had routine postsurgical surveillance with imaging 
studies, including chest CT, but the frequency and choice of 
imaging modality was not standardized.
Statistical Analysis
The Mann-Whitney U test was used to test for an asso-
ciation between LVI and the presence of involved regional 
LNs. Primary tumor size, type of surgery (wedge/segment-
ectomy versus lobectomy/pneumonectomy), thoractomy ver-
sus a video-assisted thoracoscopic surgical (VATS) approach, 
histology, visceral pleural invasion, grade, and primary tumor 
location (right versus left, upper/middle versus lower) were 
also included in this assessment. Factors with a p value of 
0.1 or less were included in a multivariate ordinal regres-
sion. Patients without regional LN sampling/dissection were 
excluded from this part of the analysis.
Univariate and multivariate analyses were also per-
formed to examine clinical and pathological factors associated 
with LF, development of distant metastases (DM), and OS, 
including LVI, type of surgical resection (thoracotomy versus 
VATS), size of primary tumor, number of hilar LNs sampled, 
number of hilar LNs involved, number of mediastinal LN sta-
tions sampled, number of mediastinal LNs involved, tumor 
histology (squamous/large-cell versus others),18 tumor grade, 
visceral pleural invasion, stage, adjuvant chemotherapy, age, 
and sex. Factors with a p value of 0.1 or less on univariate 
analysis were included in the multivariate model. For the LF 
analysis, patients with positive margins and/or those receiving 
postoperative radiation were excluded. Univariate and multi-
variate analyses were also performed based on histology, with 
LF, DM, and OS examined separately in squamous-cell carci-
nomas and adenocarcinomas.
The Kaplan-Meier product-limit method19,20 was used 
to estimate 5-year recurrence probabilities and confidence 
intervals, and comparisons were made via the log-rank test. 
When generating survival curves for patients with LVI versus 
no LVI, the patients with unknown LVI status were grouped 
into the “no LVI” category. Progression-free survival was cal-
culated from the date of surgery to date of treatment failure 
(defined as local and/or distant recurrence, development of a 
second primary lung cancer, or death from any cause). Time 
to LF and time to distant failure (DF) were calculated from the 
date of surgery to date of local or distant recurrence, respec-
tively. For these analyses, patients developing what was felt to 
be a second primary lung cancer were censored on the date the 
second primary malignancy was diagnosed. Local and distant 
recurrences were scored independently (i.e., patients develop-
ing a distant recurrence were not censored for LF, but were 
assessed for LF until the date of last follow-up or death).
RESULTS
Between 1995 and 2008, 1559 patients met the inclu-
sion criteria. Median follow-up for all patients was 34 months 
and for survivors it was 40 months. Patient characteristics are 
reported in Table 1. The majority (98%) had hilar and/or medi-
astinal LN sampling/dissection at the time of surgery. The 
majority of patients were stage I, with 41% of patients with 
pathologic stage IA disease and 26% of patients with stage IB 
disease. Presence of LVI was noted in 23% of the patients.
LVI and Regional LN Involvement
Patients with no regional LN sampling were excluded 
from this analysis (n = 33). Of the remaining 1526 patients, 
1219 were pathologic N0, 235 patients were pathologic N1, 
and 72 patients were pathologic N2.
Factors associated with regional LN involvement on uni-
variate analysis included LVI, increasing size of the primary 
tumor, lobar versus sublobar resection, thoracotomy versus 
VATS approach, visceral pleural invasion, and squamous/large-
cell histology. On multivariate ordinal regression, the pres-
ence of LVI (p < 0.001), thoracotomy (p < 0.001), and lobar 
resections (p < 0.001) continued to be significant predictors of 
harboring pathologically involved regional LNs (Table 2).
In patients who underwent lobectomy or pneumonec-
tomy (n = 696), the risk of harboring ipsilateral hilar LN dis-
ease was 36% versus 21% (p < 0.001) and the risk of harboring 
mediastinal LN disease was 12% versus 5% (p < 0.001), for 
patients with and without LVI, respectively. Furthermore, 
LVI was associated with increasing number of positive LNs 
(p < 0.001), with the median number of positive LNs equal to 
one (interquartile range 1–2) for patients without LVI and two 
(interquartile range 1–4) for patients with LVI.
LVI and Risk of Local Recurrence
For this analysis, patients with positive surgical margins 
and those receiving postoperative radiation were excluded, 
leaving 1458 evaluable patients. On univariate analysis, LVI 
was associated with statistically significant increased risk of 
LF with Kaplan-Meier estimates of 5-year local control of 
79% versus 71% (p = 0.001) (Fig. 1). However, on multivari-
ate analysis this association was lost (Table 4).
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When examining the effect of LVI on a stage-by-stage 
basis, a statistically significant detriment in local control was seen 
in patients with stage IB disease with LVI versus stage IB without 
LVI (61% versus 81%, p < 0.01). Presence of LVI was not statisti-
cally significant for LF in the other stage groups (Table 3).
LVI and DM, Recurrence-Free Survival, and OS
The presence of LVI was found to be significantly asso-
ciated with a detriment in freedom from DM as depicted in 
Figure 2 (57% versus 73% at 5 years, p < 0.001). This remained 
significant on multivariate analysis (Table 4).
The presence of LVI was also associated with increased 
risk of death (5-year OS 31% versus 56%, p < 0.001) 
(Fig. 3), which remained significant on multivariate analysis 
(Table 4). Adjuvant chemotherapy was also associated with 
improved OS on multivariate analysis (p < 0.001), and seemed 
to improve the 5-year survival for patients with LVI (32% ver-
sus 60%, p = 0.001) and for patients without LVI (49% versus 
69%, p < 0.001). In addition, when examined by histology, 
LVI was strongly associated with increased risk of developing 
DM (hazard ratio [HR] = 1.75, p = 0.006) and death (HR = 
1.53, p = 0.003) on multivariate analysis in adenocarcinomas. 
Multivariate analysis did not find LVI to be statistically sig-
nificant for DM (HR = 1.08, p = 0.75) or death (HR = 1.23, 
p = 0.11) in squamous-cell carcinoma.
DISCUSSION
LVI is an adverse prognostic factor in many other solid 
tumors and its presence is an independent indication for post-
operative radiotherapy in head and neck and multiple gyneco-
logical malignancies. The presence of LVI does not currently 
influence treatment recommendations in NSCLC.
In the present study, the presence of LVI within the pri-
mary tumor was independently associated with a higher risk 
that regional LNs were pathologically involved. Such infor-
mation could be useful when determining treatment recom-
mendations for patients who do not undergo regional LN 
sampling/dissection at the time of surgery or in patients with-
out LN sampling before undergoing definitive radiotherapy. 
Not surprisingly, increased risk of regional node involvement 
was also associated with lobectomy compared with sublobar 
resection, likely because of the absence of LN dissection or 
a limited number of LNs retrieved with most sublobar resec-
tions. In addition, open thoracotomy was also associated with 
increased risk of regional node involvement, perhaps because 
patients not eligible for a VATS procedure had a greater extent 
of the disease.
The therapy of NSCLC is now being driven by histology, 
along with the presence of validated predictive biomarkers 
TABLE 1.  Patient Characteristics
Characteristic
Age (yrs)
 Median 67
 Range 20–91
Race
 African-American 202 (13%)
 White 1328 (85%)
 Other 29 (2%)
Sex
 Male 833 (53%)
 Female 726 (47%)
Pathologic stage (TNM 7)
 IA 638 (41%)
 IB 411 (26%)
 IIA 272 (17%)
 IIB  124 (10%)
 IIIA 112 (7%)
 IIIB 2 (0.1%)
Histology
 Adenocarcinoma 734 (47%)
 Squamous cell 561 (36%)
 Large cell 93 (6%)
 Bronchioloalveolar 40 (3%)
 Adenosquamous 21 (1%)
 NSCLC NOS 110 (7%)
Surgical Approach
 Open 795 (51%)
 VATS 764 (49%)
Surgical Procedure
 Wedge/Segmentectomy 305 (20%)
 Lobectomya 1154 (74%)
 Pneumonectomy 100 (6%)
Mediastinal sampling/dissection
 Yes 1361 (87%)
 No 198 (13%)
Lymphovascular space invasion
 Yes 352 (23%)
 No 1107 (71%)
 Unknown 100 (6%)
Visceral Pleural Invasion
 Yes 366 (24%)
 No 1128 (72%)
 Unknown 65 (4%)
Chemotherapy
 Yes 184 (12%)
 No 1375 (88%)
NSCLC NOS, non–small-cell carcinoma not otherwise specified; VATS, video-
assisted thoracoscopic surgery; TNM, tumor, node, metastasis.
aIncluding bilobectomy and sleeve lobectomy.
TABLE 2. Factors Associated with Regional Lymph Node 
Involvement
Factors p Valuea
Lobectomy versus wedge/ segmentectomy <0.01
Lymphovascular invasion <0.01
Tumor size 0.094
Squamous/large cell versus adenocarcinoma 0.80
Moderate/high grade versus low grade 0.12
Open resection versus VATS approach <0.01
Visceral pleural invasion 0.08
aMultivariate ordinal regression analysis.
VATS, video-assisted thoracoscopic surgical.
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TABLE 3. Local Control Stage by Stage Stratified by Lymphovascular Invasion
Stage
5-Year Local 
Control (%) 95% CI (%) p Value
IA 86 82–90 0.43
 Lymphovascular invasion 92 85–99
 No lymphovascular invasion 85 81–89%
IB 77 71–84 <0.01
 Lymphovascular invasion  61 43–79
 No lymphovascular invasion 81 74–87
IIA 63 54–72 0.22
 Lymphovascular invasion 59 44–74
 No lymphovascular invasion 65 54–76
IIB 63 48–77 0.45
 Lymphovascular invasion 60 32–89
 No lymphovascular invasion 62 46–79
IIIA 69 51–86 0.94
 Lymphovascular invasion 67 38–97
 No lymphovascular invasion 70 48–91
CI, confidence interval.
FIGURE 1. Local control based on 
the presence or absence of LVI. LVI, 
lymphovascular space invasion.
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FIGURE 2.  Freedom from distant 
metastasis based on the presence 
or absence of LVI. LVI, lymphovas-
cular space invasion.
TABLE 4.  Multivariate Analyses for Local Recurrence, Distant Metastases, and Overall Survival
Factorsa
Local Failure Distant Metastases Overall Survival
Hazard 
Ratio 95% CI p Value
Hazard 
Ratio 95% CI p Value
Hazard 
Ratio 95% CI p Value
Surgical procedure
 Wedge/ segmentectomy 1.78 1.23–2.58 <0.01 1.56 1.30–1.88 <0.01
 ≥Lobectomy
Lymphovascular invasion
 Yes 1.23 0.87–1.76 0.25 1.52 1.13–2.02 <0.01 1.25 1.05–1.51 0.02
 No
Age (per yr) 0.99 0.97–0.99 0.03 1.02 1.01–1.03 <0.01
Tumor size (per cm) 1.13 1.05–1.22 <0.01 1.16 1.10–1.23 <0.01 1.08 1.04–1.13 <0.01
Visceral pleural invasion
 Yes 2.07 1.48–2.89 <0.01 1.30 0.96–1.76 0.09 1.12 0.93–1.36 0.24
 No
Grade
 Moderate/high 1.66 0.86–3.21 0.13 1.42 0.86–2.35 0.17 1.33 1.00–1.77 0.05
 Low
Histology
 Squamous or large cell 1.48 1.07–2.04 0.02 1.13 0.96–1.32 0.15
 Non-squamous
VATS approach
 Yes 0.91 0.65–0.91 <0.01 0.84 0.63–1.11 0.22 0.89 0.75–1.05 0.16
 No (Continued)
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TABLE 4. (Continued)
Factorsa
Local Failure Distant Metastases Overall Survival
Hazard 
Ratio 95% CI p Value
Hazard 
Ratio 95% CI p Value
Hazard 
Ratio 95% CI p Value
Adjuvant chemotherapy
 Yes 0.66 0.41–1.06 0.09 0.67 0.46–0.98 0.04 0.35 0.24–0.50 <0.01
 No
Male sex
 Yes 1.13 0.83–1.55 0.44 1.32 1.13–1.55 <0.01
 No
Number of N1 LNs sampled (per node) 0.99 0.96–1.03 0.69
Number of involved N1 LNs (per node) 1.12 0.98–1.29 0.10 1.12 1.00–1.25 0.05 1.12 1.04–1.21 <0.01
Number of involved N2 LNs (per node) 1.31 0.91–1.88 0.15 1.37 1.06–1.77 0.02 1.31 1.09–1.57 <0.01
aOnly factors with a p value less than 0.1 on univariate analysis were included in the multivariate model. The second factor listed is the reference set.
LN, lymph node; CI, confidence interval; VATS, video-assisted thoracoscopic surgical.
FIGURE 3. Overall survival 
based on the presence or 
absence of LVI. LVI, lymphovas-
cular space invasion.
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for erlotinib and crizotinib.21,22 Interestingly, when patients were 
analyzed according to histology, the association of LVI with 
increased risk of DM and death was only found in adenocarcino-
mas. Currently, the presence of LVI is rarely reported in pathol-
ogy reports from core needle biopsies of lung masses, as tumor 
stroma containing vessels and lymphatics must be present to make 
such a determination. Improving biopsy techniques to allow for 
more adequate tumor sampling is necessary to routinely report 
presence or absence of LVI and determine tumor histology and 
molecular status. Although the present study demonstrates LVI to 
be a poor prognostic factor in resected lung specimens, a recently 
published study has also demonstrated that LVI in core needle 
biopsies is associated with poor outcome in patients undergoing 
chemoradiation.16 We believe that refining tumor characterization 
at core needle biopsy is an important step forward.
The presence of LVI was associated with a higher risk of LF 
on univariate analysis. This distinction was most evident in stage 
IB patients (i.e., those with larger primary tumors but no evidence 
of regional LN involvement). In this patient population, LVI has 
been associated with inferior OS in multiple studies,11,14 but the 
impact of LVI on LF was not evaluated. Although significant on 
univariate analysis, LVI did not remain statistically significant for 
LF for the entire cohort on multivariate analysis. In contrast, other 
pathologic factors were strongly associated with LF, including 
visceral pleural invasion and squamous/large-cell histology.
Our data indicate that LVI is more strongly associ-
ated with DF as opposed to LF. Patients with LVI had sig-
nificantly increased risk of developing DM and a lower rate 
of survival. Other studies have demonstrated an association 
between LVI and decreased recurrence-free survival and OS 
in NSCLC.12–14 The present study is the first to evaluate LF 
and DF as distinct entities in association with LVI. Why LVI 
is more strongly associated with DF and death in adenocarci-
nomas is unknown.
Limitations to the present study do exist. First, given its ret-
rospective nature, no centralized confirmatory pathologic review 
was possible. However, the vast majority of specimens were 
analyzed by a single pathologist who specializes in pulmonary 
pathology. Second, lymphatic invasion and vascular invasion 
were analyzed together and not independent of one another. It is 
not known if one is of greater importance than the other. Finally, 
although the sample cohort was large, the majority of patients 
had stage I disease. Statistical power may be limited in stage II 
and III patients, the subset of patients with the highest risk of LF.
In conclusion, the presence of LVI is associated with an 
increased risk of developing DM and death after surgery for 
early-stage NSCLC. LVI alone does not seem to be a strong 
enough risk factor for LF alone to warrant postoperative radi-
ation therapy in NSCLC. The presence of LVI is associated 
with an increased risk of developing DM and may be helpful 
in the decision paradigm for adjuvant chemotherapy.
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